METHOD FOR PREDICTING CANCER RESPONSE TO IMMUNOTHERAPY TREATMENT WITH ANTI-PD1

Description:

Cancer is one of the most studied diseases in recent years, due to its high incidence and mortality. The use of immune control inhibitors, ICBs, has revolutionized cancer treatment, as acceptable toxicity and long-lasting response have been demonstrated in responders. The use of the programmed death ligand inhibitor (anti-PD1) is a common treatment in patients with advanced melanomas, which has been shown to have a 20% higher response rate than with chemotherapy and with better tolerability. However, a percentage of patients are insensitive or develop resistance, so it is necessary to have a pattern of predictive biomarkers that allows deciding whether or not to use anti-PD1. In this invention, a molecular biomarker profile is identified, which allows patients to be classified according to their response profile, based on gene expression variations.

Keywords:

Cancer, Forecast, Immunotherapy, Anti-Pd1, Gene Expression

Sectors:

Biotechnology, Health

Areas:

Health Sciences, Diagnosis, Therapeutics, Biotechnology, Genetics

Advantages:

This invention has the following advantages: - It allows to determine in advance if the anti-PD1 treatment is suitable for the patient. - It reduces the economic costs and the adverse effects associated with the use of non-responsive treatments for certain patients.

Uses and Applications:

Invention belonging to the Biotech-Pharma sector. Specifically, the prognosis of treatment in oncology.

Patent Number: EP4069869A0

Applicants: Universidad De Málaga, Junta De Andalucía. Consejería De Salud. Servicio Andaluz De Salud.

Inventors: Mª. Isabel Barragán Mallofret, Martina Alvarez Perez, Miguel Ángel Berciano Guerrero, Manuel Cobo Dols, Alicia Garrido Aranda, Alfonso Sánchez Muñoz, Francisco Javier Oliver Martos, Pedro Jiménez Gallego, Emilio Alba Conejo

Filing Date: 04/12/2019

Protection Level: International

Processing Status: International protection application